Tag: Differentiated thyroid carcinoma

Iodine 131 treatment for differentiated thyroid carcinoma in patients with end stage renal failure: dosimetric, radiation safety, and practical considerations

Posted on by

Caliope Alevizaki, Michael Molfetas, Alexandros Samartzis, Barbara Vlassopoulou, Charalambos Vassilopoulos, Phoedi Rondogianni, Sofia Kottou, Valsamis Hadjiconstantinou, Maria Alevizaki

Download PDF

BACKGROUND: Iodine 131 ablation following total thyroidectomy is considered an indispensable element of successful treatment of differentiated thyroid carcinoma (Dtc). because of the essential role of the kidneys in iodine clearance, 131I therapy of Dtc in patients with end stage renal disease, particularly those maintained on haemodialysis …

Recombinant human thyroid stimulating hormone does not acutely change serum osteoprotegerin and soluble receptor activator of nuclear factor-κΒ ligand in patients under evaluation for differentiated thyroid carcinoma*

Posted on by

Massimo Giusti, Francesca Cecoli, Carla Ghiara, Alessandro Rubinacci, Isabella Villa, Domenico Cavallero, Laura Mazzuoli, Michele Mussap, Roberto Lanzi, Francesco Minuto

Download PDF

OBJECTIVE: Some extra-thyroid actions of thyroid stimulating hormone (TSH), such as an in vitro action on bone, have been described. Our aim was to evaluate in vivo the acute effect of a recombinant human TSH (rhTSH)-induced TSH surge on Osteoprotegerin (OPG) and receptor activator of the nuclear factor-κB (RANK-L) levels in patients under levo-thyroxine (L-T4) therapy…